---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-216156"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:06:34.206459+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M

## Summary
- Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.
- Net income $8.7M ($0.07 diluted EPS) vs $20.7M ($0.15) a year ago; Adjusted net income $11.3M.
- Advanced Wound Care rev $113.8M (+2%), Surgical & Sports Medicine $7.6M (-35%).
- PuraPly rev $69.4M (+84%); non-PuraPly $52.0M (-39%).
- FY2022 guidance: net revenue $465M-$490M; Adj. EBITDA $60M-$74M.

## SEC filing metadata
- accession: 0001193125-22-216156
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312522216156/0001193125-22-216156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312522216156/d382521d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-216156
- JSON: https://secwatch.observer/filing/0001193125-22-216156.json
- Plain text: https://secwatch.observer/filing/0001193125-22-216156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.